Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering
February 06, 2023 16:08 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its intention to offer, subject to market and other conditions, $175,000,000...
Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results
February 06, 2023 16:07 ET
|
Collegium Pharmaceutical, Inc.
-Results at or above high-end of 2022 earnings guidance- -Final fourth quarter and full year 2022 financial results to be announced after market closes on Thursday, February 23- ...
Collegium Provides 2023 Financial Guidance
January 04, 2023 08:00 ET
|
Collegium Pharmaceutical, Inc.
– Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million – – Adjusted Operating Expenses* Expected in the Range of $135.0 Million to $145.0 Million – – Adjusted EBITDA*...
Appeals Court Affirms Validity of Collegium’s Belbuca® Patents
December 22, 2022 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Federal Circuit...
Collegium to Participate in Piper Sandler 34th Annual Healthcare Conference
November 22, 2022 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will...
Collegium Reports Third Quarter 2022 Financial Results
November 03, 2022 16:01 ET
|
Collegium Pharmaceutical, Inc.
– Generated Record Net Revenue of $127.0 Million – – Completed Xtampza® ER Contract Renegotiations, Confirmed Xtampza ER Gross-To-Net Will be Less Than 65% Beginning January 2023 – – Returned...
Collegium to Report Third Quarter 2022 Financial Results on November 3, 2022
October 20, 2022 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report third...
Collegium Announces 11 Poster Presentations at PAINWeek 2022 National Conference
August 30, 2022 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that 11 poster...
Collegium Reports Second Quarter 2022 Financial Results
August 04, 2022 16:01 ET
|
Collegium Pharmaceutical, Inc.
– Generated Record Net Revenue of $123.5 Million – – BDSI Integration Complete; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million – – Raises Full Year Adjusted...
Collegium to Report Second Quarter 2022 Financial Results on August 4, 2022
July 21, 2022 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report second...